Gal-9 levels were significantly reduced (3.04 ng/mL, IQR 2.18–3.91 ng/mL versus 2.09 ng/mL, IQR 1.58–2.60 ng/mL, p < 0.001), and so were FABP1 levels (p = 0.054), after 12 months of JAKi therapy in RA patients (Figure 4F). This evidence concerns the gene LGALS9 and rheumatoid arthritis.